SCHEMBL732106

SCHEMBL732106

O=Cc1ccc2nccc(-c3ccncc3)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 12/20 0.60
PIK3CD O00329 2/20 0.60
PIK3CB P42338 2/20 0.60
MTOR P42345 2/20 0.60
PIK3CG P48736 2/20 0.60
GAK O14976 1/20 0.60
RPS6KA4 O75676 1/20 0.60
STK10 O94804 1/20 0.60
PIM1 P11309 1/20 0.60
CSNK2A2 P19784 1/20 0.60
MAP2K2 P36507 1/20 0.60
CSNK1D P48730 1/20 0.60
CLK1 P49759 1/20 0.60
CLK2 P49760 1/20 0.60
CSNK1G2 P78368 1/20 0.60
MAP2K1 Q02750 1/20 0.60
DYRK1A Q13627 1/20 0.60
AAK1 Q2M2I8 1/20 0.60
Q6ZSR9 Q6ZSR9 1/20 0.60
TAOK1 Q7L7X3 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30827802 1.00 PIK3CA (0.60) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL730195 0.80 PIK3CA (0.84) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL730188 0.78 PIK3CA (0.87) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL21473072 0.77 PIK3CA (0.50) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL16144558 0.77 PIK3CA (0.60) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL25947046 0.77 PIK3CA (0.50) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL4188009 0.77 PIK3CA (0.41) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL4191687 0.77 TOP2A (0.43) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL729729 0.76 IP6K1 (0.50) PIK3CAPIK3CDPIK3CBMTORPIK3CG
SCHEMBL28509305 0.76 ACVR1 (0.49) PIK3CAPIK3CDPIK3CBMTORPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117800921-B Imidazolidine diketone HDAC inhibitor, preparation method and application 南京市鸿舜医药科技有限公司 2024-06-11 CN disclosed
CN-117800921-A Imidazolidine diketone HDAC inhibitor, preparation method and application 南京市鸿舜医药科技有限公司 2024-04-02 CN disclosed
EP-2596793-B1 Quinoline derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-07-08 EP disclosed
EP-2596793-B1 Quinoline derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-07-08 EP disclosed
US-20140296224-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2014-10-02 US disclosed
US-20140296224-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2014-10-02 US disclosed
US-8785433-B2 Quinoline derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-22 US disclosed
US-8785433-B2 Quinoline derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-22 US disclosed
US-20140100234-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-04-10 US disclosed
US-8633187-B2 Quinoline derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2014-01-21 US disclosed
EP-2004189-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 EP disclosed
US-20080300239-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300239-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300239-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
WO-2008144463-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 WO disclosed
WO-2008144463-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 WO disclosed
WO-2008144464-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 WO disclosed
WO-2008144464-A1 QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 WO disclosed
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS DARCY MICHAEL GERARD 2008-10-16 US disclosed
WO-2007136940-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS PI4KA, JAK3, PIK3CD PIK3CA 14/4885PIK3CD 3/4885PIK3CB 8/4885
US-20140100234-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PIK3CG, PIK3CB PIK3CA 6/4885PIK3CD 1/4885PIK3CB 3/4885
US-20140296224-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PIK3CG, PIK3CB PIK3CA 6/4885PIK3CD 1/4885PIK3CB 3/4885
US-20080300239-A1 QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PIK3CG, PIK3CB PIK3CA 6/4885PIK3CD 1/4885PIK3CB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.